<?xml version="1.0" encoding="UTF-8"?>
<protein>
  <version>3.5</version>
  <creation_date>2013-01-15 19:07:47 -0700</creation_date>
  <update_date>2013-01-15 19:07:47 -0700</update_date>
  <accession>HMDBP02751</accession>
  <secondary_accessions>
    <accession>8256</accession>
  </secondary_accessions>
  <protein_type>Enzyme</protein_type>
  <synonyms>
    <synonym>PGI receptor</synonym>
    <synonym>PGI2 receptor</synonym>
    <synonym>Prostaglandin I2 receptor</synonym>
    <synonym>Prostanoid IP receptor</synonym>
  </synonyms>
  <gene_name>PTGIR</gene_name>
  <general_function>Involved in G-protein coupled receptor protein signaling pathway</general_function>
  <specific_function>Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase</specific_function>
  <pathways>
  </pathways>
  <metabolite_associations>
    <metabolite>
      <accession>HMDB01335</accession>
      <name>Prostaglandin I2</name>
    </metabolite>
    <metabolite>
      <accession>HMDB14518</accession>
      <name>Treprostinil</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15220</accession>
      <name>Iloprost</name>
    </metabolite>
    <metabolite>
      <accession>HMDB15291</accession>
      <name>Dinoprost Tromethamine</name>
    </metabolite>
  </metabolite_associations>
  <go_classifications>
    <go_class>
      <category>process</category>
      <description>signaling</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>cell surface receptor linked signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>process</category>
      <description>g-protein coupled receptor protein signaling pathway</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>cell part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>membrane part</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>intrinsic to membrane</description>
      <go_id/>
    </go_class>
    <go_class>
      <category>component</category>
      <description>integral to membrane</description>
      <go_id/>
    </go_class>
  </go_classifications>
  <subcellular_locations>
    <subcellular_location>Cell membrane</subcellular_location>
    <subcellular_location>Multi-pass membrane protein</subcellular_location>
  </subcellular_locations>
  <gene_properties>
    <chromosome_location>Chromosome:1</chromosome_location>
    <locus>19q13.3</locus>
    <gene_sequence>&gt;1161 bp
ATGGCGGATTCGTGCAGGAACCTCACCTACGTGCGGGGCTCGGTGGGGCCGGCCACCAGC
ACCCTGATGTTCGTGGCCGGTGTGGTGGGCAACGGGCTGGCCCTGGGCATCCTGAGCGCA
CGGCGACCGGCGCGCCCCTCGGCCTTCGCGGTGCTGGTCACCGGACTGGCGGCCACCGAC
CTGCTGGGCACCAGCTTCCTGAGCCCGGCCGTGTTCGTGGCCTATGCGCGCAACAGCTCC
CTGCTGGGCCTGGCCCGAGGCGGCCCCGCCCTGTGCGATGCCTTCGCCTTCGCCATGACC
TTCTTCGGCCTGGCGTCCATGCTCATCCTCTTTGCCATGGCCGTGGAGCGCTGCCTGGCG
CTGAGCCACCCCTACCTCTACGCGCAGCTGGACGGGCCCCGCTGCGCCCGCCTGGCGCTG
CCAGCCATCTACGCCTTCTGCGTCCTCTTCTGCGCGCTGCCCCTGCTGGGCCTGGGCCAA
CACCAGCAGTACTGCCCCGGCAGCTGGTGCTTCCTCCGCATGCGCTGGGCCCAGCCGGGC
GGCGCCGCCTTCTCGCTGGCCTACGCCGGCCTGGTGGCCCTGCTGGTGGCTGCCATCTTC
CTCTGCAACGGCTCGGTCACCCTCAGCCTCTGCCGCATGTACCGCCAGCAGAAGCGCCAC
CAGGGCTCTCTGGGTCCACGGCCGCGCACCGGAGAGGACGAGGTGGACCACCTGATCCTG
CTGGCCCTCATGACAGTGGTCATGGCCGTGTGCTCCCTGCCTCTCACGATCCGCTGCTTC
ACCCAGGCTGTCGCCCCTGACAGCAGCAGTGAGATGGGGGACCTCCTTGCCTTCCGCTTC
TACGCCTTCAACCCCATCCTGGACCCCTGGGTCTTCATCCTTTTCCGCAAGGCTGTCTTC
CAGCGACTCAAGCTCTGGGTCTGCTGCCTGTGCCTCGGGCCTGCCCACGGAGACTCGCAG
ACACCCCTTTCCCAGCTCGCCTCCGGGAGGAGGGACCCAAGGGCCCCCTCTGCTCCTGTG
GGAAAGGAGGGGAGCTGCGTGCCTTTGTCGGCTTGGGGCGAGGGGCAGGTGGAGCCCTTG
CCTCCCACACAGCAGTCCAGCGGCAGCGCCGTGGGAACGTCGTCCAAAGCAGAAGCCAGC
GTCGCCTGCTCCCTCTGCTGA</gene_sequence>
  </gene_properties>
  <protein_properties>
    <residue_number>386</residue_number>
    <molecular_weight>40955.5</molecular_weight>
    <theoretical_pi>8.53</theoretical_pi>
    <pfams>
      <pfam>
        <name>7tm_1</name>
        <pfam_id>PF00001</pfam_id>
      </pfam>
    </pfams>
    <transmembrane_regions>
      <region>17-38</region>
      <region>52-76</region>
      <region>95-115</region>
      <region>135-158</region>
      <region>182-208</region>
      <region>236-260</region>
      <region>275-295</region>
    </transmembrane_regions>
    <signal_regions>
      <region>None</region>
    </signal_regions>
    <protein_sequence>&gt;Prostacyclin receptor
MADSCRNLTYVRGSVGPATSTLMFVAGVVGNGLALGILSARRPARPSAFAVLVTGLAATD
LLGTSFLSPAVFVAYARNSSLLGLARGGPALCDAFAFAMTFFGLASMLILFAMAVERCLA
LSHPYLYAQLDGPRCARLALPAIYAFCVLFCALPLLGLGQHQQYCPGSWCFLRMRWAQPG
GAAFSLAYAGLVALLVAAIFLCNGSVTLSLCRMYRQQKRHQGSLGPRPRTGEDEVDHLIL
LALMTVVMAVCSLPLTIRCFTQAVAPDSSSEMGDLLAFRFYAFNPILDPWVFILFRKAVF
QRLKLWVCCLCLGPAHGDSQTPLSQLASGRRDPRAPSAPVGKEGSCVPLSAWGEGQVEPL
PPTQQSSGSAVGTSSKAEASVACSLC</protein_sequence>
  </protein_properties>
  <genbank_protein_id/>
  <uniprot_id>P43119</uniprot_id>
  <uniprot_name>PI2R_HUMAN</uniprot_name>
  <pdb_ids>
  </pdb_ids>
  <genbank_gene_id>L29016</genbank_gene_id>
  <genecard_id>PTGIR</genecard_id>
  <geneatlas_id>PTGIR</geneatlas_id>
  <hgnc_id>HGNC:9602</hgnc_id>
  <general_references>
    <reference>
      <reference_text>Boie Y, Rushmore TH, Darmon-Goodwin A, Grygorczyk R, Slipetz DM, Metters KM, Abramovitz M: Cloning and expression of a cDNA for the human prostanoid IP receptor.  J Biol Chem. 1994 Apr 22;269(16):12173-8.</reference_text>
      <pubmed_id>7512962</pubmed_id>
    </reference>
    <reference>
      <reference_text>Katsuyama M, Sugimoto Y, Namba T, Irie A, Negishi M, Narumiya S, Ichikawa A: Cloning and expression of a cDNA for the human prostacyclin receptor.  FEBS Lett. 1994 May 9;344(1):74-8.</reference_text>
      <pubmed_id>7514139</pubmed_id>
    </reference>
    <reference>
      <reference_text>Nakagawa O, Tanaka I, Usui T, Harada M, Sasaki Y, Itoh H, Yoshimasa T, Namba T, Narumiya S, Nakao K: Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system. Circulation. 1994 Oct;90(4):1643-7.</reference_text>
      <pubmed_id>7923647</pubmed_id>
    </reference>
    <reference>
      <reference_text>Ogawa Y, Tanaka I, Inoue M, Yoshitake Y, Isse N, Nakagawa O, Usui T, Itoh H, Yoshimasa T, Narumiya S, et al.: Structural organization and chromosomal assignment of the human prostacyclin receptor gene. Genomics. 1995 May 1;27(1):142-8.</reference_text>
      <pubmed_id>7665161</pubmed_id>
    </reference>
    <reference>
      <reference_text>Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.</reference_text>
      <pubmed_id>15489334</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miggin SM, Lawler OA, Kinsella BT: Investigation of a functional requirement for isoprenylation by the human prostacyclin receptor. Eur J Biochem. 2002 Mar;269(6):1714-25.</reference_text>
      <pubmed_id>11895442</pubmed_id>
    </reference>
    <reference>
      <reference_text>Miggin SM, Lawler OA, Kinsella BT: Palmitoylation of the human prostacyclin receptor. Functional implications of palmitoylation and isoprenylation. J Biol Chem. 2003 Feb 28;278(9):6947-58. Epub 2002 Dec 17.</reference_text>
      <pubmed_id>12488443</pubmed_id>
    </reference>
    <reference>
      <reference_text>Giguere V, Gallant MA, de Brum-Fernandes AJ, Parent JL: Role of extracellular cysteine residues in dimerization/oligomerization of the human prostacyclin receptor. Eur J Pharmacol. 2004 Jun 21;494(1):11-22.</reference_text>
      <pubmed_id>15194446</pubmed_id>
    </reference>
  </general_references>
  <metabolite_references>
    <metabolite_reference>
      <metabolite>
        <name>Treprostinil</name>
        <accession>HMDB14518</accession>
      </metabolite>
      <reference>
        <reference_text>Falcetti E, Hall SM, Phillips PG, Patel J, Morrell NW, Haworth SG, Clapp LH: Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med. 2010 Nov 1;182(9):1161-70. Epub 2010 Jul 9.</reference_text>
        <pubmed_id>20622039</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Treprostinil</name>
        <accession>HMDB14518</accession>
      </metabolite>
      <reference>
        <reference_text>Sprague RS, Bowles EA, Hanson MS, DuFaux EA, Sridharan M, Adderley S, Ellsworth ML, Stephenson AH: Prostacyclin analogs stimulate receptor-mediated cAMP synthesis and ATP release from rabbit and human erythrocytes. Microcirculation. 2008 Jul;15(5):461-71.</reference_text>
        <pubmed_id>18574748</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Treprostinil</name>
        <accession>HMDB14518</accession>
      </metabolite>
      <reference>
        <reference_text>Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension.  Pharmacol Ther. 2004 May;102(2):139-53.</reference_text>
        <pubmed_id>15163595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Treprostinil</name>
        <accession>HMDB14518</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Takamatsu H, Tsukada H, Watanabe Y, Cui Y, Kataoka Y, Hosoya T, Suzuki M, Watanabe Y: Specific ligand for a central type prostacyclin receptor attenuates neuronal damage in a rat model of focal cerebral ischemia. Brain Res. 2002 Jan 25;925(2):176-82.</reference_text>
        <pubmed_id>11792366</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Crutchley DJ, Solomon DE, Conanan LB: Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism. Arterioscler Thromb. 1992 Jun;12(6):664-70.</reference_text>
        <pubmed_id>1375507</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schror K, Kirchrath JM, Seeger W, Rose F: Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007 Jan 26;8:4.</reference_text>
        <pubmed_id>17257398</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN: Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007 Feb;117(2):464-72.</reference_text>
        <pubmed_id>17273558</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Tsai AL, Vijjeswarapu H, Wu KK: Interaction between platelet receptor and iloprost isomers.  Biochim Biophys Acta. 1988 Jul 21;942(2):220-6.</reference_text>
        <pubmed_id>2456096</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension.  Pharmacol Ther. 2004 May;102(2):139-53.</reference_text>
        <pubmed_id>15163595</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Anderson JR, Nawarskas JJ: Pharmacotherapeutic management of pulmonary arterial hypertension.  Cardiol Rev. 2010 May-Jun;18(3):148-62.</reference_text>
        <pubmed_id>20395700</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Mubarak KK: A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan;104(1):9-21. Epub 2009 Aug 15.</reference_text>
        <pubmed_id>19683911</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Iloprost</name>
        <accession>HMDB15220</accession>
      </metabolite>
      <reference>
        <reference_text>Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ: Inhaled iloprost for the control of pulmonary hypertension.  Vasc Health Risk Manag. 2009;5(1):465-74.</reference_text>
        <pubmed_id>19475782</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dinoprost Tromethamine</name>
        <accession>HMDB15291</accession>
      </metabolite>
      <reference>
        <reference_text>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there?  Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</reference_text>
        <pubmed_id>17139284</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dinoprost Tromethamine</name>
        <accession>HMDB15291</accession>
      </metabolite>
      <reference>
        <reference_text>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets.  Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</reference_text>
        <pubmed_id>17016423</pubmed_id>
      </reference>
    </metabolite_reference>
    <metabolite_reference>
      <metabolite>
        <name>Dinoprost Tromethamine</name>
        <accession>HMDB15291</accession>
      </metabolite>
      <reference>
        <reference_text>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database.  Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</reference_text>
        <pubmed_id>11752352</pubmed_id>
      </reference>
    </metabolite_reference>
  </metabolite_references>
</protein>
